These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 38042600)

  • 1. Application of multi-armed bandits to dose-finding clinical designs.
    Kojima M
    Artif Intell Med; 2023 Dec; 146():102713. PubMed ID: 38042600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Keyboard design for phase I drug-combination trials.
    Pan H; Lin R; Zhou Y; Yuan Y
    Contemp Clin Trials; 2020 May; 92():105972. PubMed ID: 32151751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative review of novel model-assisted designs for phase I clinical trials.
    Zhou H; Murray TA; Pan H; Yuan Y
    Stat Med; 2018 Jun; 37(14):2208-2222. PubMed ID: 29682777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the relative efficiency of model-assisted designs: a conditional approach.
    Lin R; Yuan Y
    J Biopharm Stat; 2019; 29(4):648-662. PubMed ID: 31258039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive designs for best treatment identification with top-two Thompson sampling and acceleration.
    Wang J; Tiwari R
    Pharm Stat; 2023; 22(6):1089-1103. PubMed ID: 37571869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of design methods for a safety run-in phase of a phase II clinical trial.
    Ji L; Alonzo TA
    Clin Trials; 2023 Apr; 20(2):181-191. PubMed ID: 36628921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial.
    Kojima M
    BMC Med Res Methodol; 2022 Apr; 22(1):97. PubMed ID: 35382745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approximate Bayesian computation design for phase I clinical trials.
    Jin H; Du W; Yin G
    Stat Methods Med Res; 2022 Dec; 31(12):2310-2322. PubMed ID: 36031856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Data-dependent early completion of dose-finding trials for drug-combination.
    Kojima M
    Stat Methods Med Res; 2023 Apr; 32(4):820-828. PubMed ID: 36775992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uniformly most powerful Bayesian interval design for phase I dose-finding trials.
    Lin R; Yin G
    Pharm Stat; 2018 Nov; 17(6):710-724. PubMed ID: 30066466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian optimization design for dose-finding based on toxicity and efficacy outcomes in phase I/II clinical trials.
    Takahashi A; Suzuki T
    Pharm Stat; 2021 May; 20(3):422-439. PubMed ID: 33258282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-stage dose expansion cohort (MSDEC) design with Bayesian stopping rule.
    Wang S; Tan M
    J Biopharm Stat; 2022 Jul; 32(4):600-612. PubMed ID: 35699319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy.
    Liu R; Lin J; Li P
    Contemp Clin Trials; 2020 Sep; 96():106083. PubMed ID: 32659438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A two-stage Bayesian adaptive design for minimum effective dose (MinED)-based dosing-finding trials.
    Mu R; Xu G; Liu G; Pan H
    Contemp Clin Trials; 2021 Sep; 108():106504. PubMed ID: 34303862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporating historical information to improve phase I clinical trials.
    Zhou Y; Lee JJ; Wang S; Bailey S; Yuan Y
    Pharm Stat; 2021 Nov; 20(6):1017-1034. PubMed ID: 33793044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
    Du Y; Yin J; Sargent DJ; Mandrekar SJ
    J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Borrowing historical information to improve phase I clinical trials using meta-analytic-predictive priors.
    Chen X; Zhang J; Jiang Q; Yan F
    J Biopharm Stat; 2022 Jan; 32(1):34-52. PubMed ID: 35594366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trials.
    Takahashi A; Suzuki T
    Int J Biostat; 2021 Apr; 18(1):39-56. PubMed ID: 33818029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competing designs for drug combination in phase I dose-finding clinical trials.
    Riviere MK; Dubois F; Zohar S
    Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.